Related Experiment Videos
Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple
1Department of Neurology, University of California, San Francisco, Calif. 94143-0114, USA. dsg@itsa.ucsf.edu
Abstract:
Therapeutic trials in multiple sclerosis, in part because of the marked intra- and inter-individual variability of its clinical course, are prone to serious flaws in both design and interpretation. As a consequence, it has been a common historical pattern that treatment regimens, which are enthusiastically recommended at one point in time, are later proven to be ineffective by more definitive studies. This review considers several recently published therapeutic trials in order to exemplify some of the difficulties that commonly arise in this area of clinical research.
Insights
Designing effective multiple sclerosis (MS) treatment trials is challenging due to patient variability. Many promising MS therapies are later found ineffective, highlighting critical research design flaws.
Area of Science:
- Neurology
- Clinical Trials
- Immunology
Background:
- Multiple sclerosis (MS) clinical courses exhibit significant intra- and inter-individual variability.
- This variability complicates the design and interpretation of therapeutic trials in MS.
- Historically, some MS treatments initially hailed as effective were later disproven by rigorous studies.
Purpose of the Study:
- To review recently published therapeutic trials in multiple sclerosis.
- To exemplify common design and interpretation difficulties encountered in MS clinical research.
Main Methods:
- Review of recently published therapeutic trials in multiple sclerosis.
- Analysis of trial designs and interpretation methodologies.
Main Results:
- Therapeutic trials in MS are frequently flawed due to inherent patient variability.
- Interpretation of trial outcomes can be misleading, leading to premature conclusions about treatment efficacy.
- Examples illustrate recurring challenges in MS clinical research.
Conclusions:
- The high variability in multiple sclerosis necessitates careful trial design and interpretation.
- More robust methodologies are required to accurately assess the efficacy of MS treatments.
- Addressing these design flaws is crucial for advancing MS therapeutics.